Stupp Roger, Pica Alessia, Mirimanoff René O, Michielin Olivier
Centre pluridisciplinaire d'oncologie, Centre hospitalier universitaire vaudois(CHUV), 46, rue du Bugnon, CH-1011 Lausanne, Suisse.
Bull Cancer. 2007 Sep;94(9):817-22.
The management of gliomas in daily clinical practice is challenging. It requires a multidisciplinary and coordinated approach involving neurosurgery, radiotherapy and, finally, chemotherapy. Important progress has been made during the last years with the introduction of a combined treatment associating standard radiotherapy with concomitant chemotherapy using temozolomide, a novel alkylating agent. For the first time in many years a new treatment strategy translated into a significant prolongation of survival. In parallel, molecular markers (e.g. loss of heterozygosity on chromosomes 1p and 19q or methylation of the methyl-guanine methyl transferase [MGMT] gene promoter) allowed for identification of distinct subtypes of glioma or prediction of treatment response. In this "Practical Guide", we describe the daily practice and aim at answering some common questions in the management of patients suffering from glioblastoma, astrocytoma, oligodendroglioma and low grade glioma. The therapeutic options presented here are based on evidences from the literature. In the absence of documented evidence, the empirical choices from our local practice are explained and justified.
在日常临床实践中,胶质瘤的管理具有挑战性。它需要一种多学科协调的方法,涉及神经外科、放射治疗,最后是化疗。在过去几年中,随着将标准放疗与使用新型烷化剂替莫唑胺的同步化疗相结合的联合治疗方法的引入,取得了重要进展。多年来,一种新的治疗策略首次转化为显著延长生存期。与此同时,分子标志物(例如1号染色体和19号染色体上的杂合性缺失或甲基鸟嘌呤甲基转移酶[MGMT]基因启动子的甲基化)有助于识别不同类型的胶质瘤或预测治疗反应。在本“实用指南”中,我们描述了日常实践,并旨在回答胶质母细胞瘤、星形细胞瘤、少突胶质细胞瘤和低级别胶质瘤患者管理中的一些常见问题。这里介绍的治疗选择基于文献证据。在没有文献证据的情况下,我们会解释并说明本地实践中的经验性选择及其依据。